Search

Your search keyword '"Trojan, Jörg"' showing total 843 results
Start Over Author "Trojan, Jörg"
843 results on '"Trojan, Jörg"'

101. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers

Author

Himmelsbach, Vera, Pinter, Matthias, Scheiner, Bernhard, Venerito, Marino, Sinner, Friedrich, Zimpel, Carolin, Marquardt, Jens, Trojan, Jörg, Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, Pinter, Matthias, Scheiner, Bernhard, Venerito, Marino, Sinner, Friedrich, Zimpel, Carolin, Marquardt, Jens, Trojan, Jörg, Waidmann, Oliver, and Finkelmeier, Fabian

Abstract

The combination of atezolizumab and bevacizumab (A + B) is the new standard of care for the systemic first-line treatment of hepatocellular carcinoma (HCC). However, up to now there are only few data on the safety and efficacy of A + B in real life. We included patients with advanced HCC treated with A + B as first-line therapy at four cancer centers in Germany and Austria between December 2018 and August 2021. Demographics, overall survival (OS), and adverse events were assessed until 15 September 2021. We included 66 patients. Most patients had compensated cirrhosis (n = 34; 52%), while Child–Pugh class B cirrhosis was observed in 23 patients (35%), and class C cirrhosis in 5 patients (8%). The best responses included a complete response (CR) in 7 patients (11%), a partial response (PR) in 12 patients (18%), stable disease (SD) in 22 patients (33%), and progressive disease in 11 patients (17%). The median progression-free (PFS) survival was 6.5 months, while the median overall survival (OS) was not reached in this cohort (6-month OS: 69%, 12-month OS: 60%, 18-month OS: 58%). Patients with viral hepatitis seemed to have a better prognosis than patients with HCC of non-viral etiology. The real-world PFS and OS were comparable to those of the pivotal IMBRAVE trial, despite including patients with worse liver function in this study. We conclude that A + B is also highly effective in a real-life setting, with manageable toxicity, especially in patients with compensated liver disease. In patients with compromised liver function (Child B and C), the treatment showed low efficacy and, therefore, it should be well considered before administration to these patients.

Published
2022

102. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma

Author

Schrecker, Christopher, Waidmann, Oliver, Youzouri, Hanan el, Trojan, Jörg, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, Koch, Christine, Schrecker, Christopher, Waidmann, Oliver, Youzouri, Hanan el, Trojan, Jörg, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, and Koch, Christine

Abstract

The prognostic role of platelet count in hepatocellular carcinoma (HCC) remains unclear, and in fact both thrombocytopenia and thrombocytosis are reported as predictors of unfavourable outcomes. This study aimed to clarify the prognostic value of preoperative platelet count in potentially resectable HCC. We retrospectively reviewed 128 patients who underwent hepatic resection for HCC at a tertiary academic centre (2007–2019). Patient data were modelled by regression analysis, and platelet count was treated as a continuous variable. 89 patients had BCLC 0/A tumours and 39 had BCLC B tumours. Platelet count was higher in patients with larger tumours and lower in patients with higher MELD scores, advanced fibrosis, and portal hypertension (p < 0.001 for all listed variables). After adjusting for BCLC stage and tumour diameter, low platelet count associated with reduced overall survival (hazard ratio 1.25 per 50/nL decrease in platelet count, 95% confidence interval (CI) 1.02–1.53, p = 0.034) and increased perioperative mortality (odds ratio 1.96 per 50/nL decrease in platelet count, 95% CI 1.19–3.53, p = 0.014). Overall, low platelet count correlates with increased liver disease severity, inferior survival, and excess perioperative mortality in resectable HCC. These insights might be applied in clinical practice to better select patients for resection.

Published
2022

103. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE

Author

Hosseini, Sabrina Khageh, Kolterer, Stefanie, Steiner, Marlene, von Manstein, Viktoria, Gerlach, Katharina, Trojan, Jörg, Waidmann, Oliver, Zeuzem, Stefan, Schulze, Jörg O., Hahn, Steffen, Steinhilber, Dieter, Gatterdam, Volker, Tampé, Robert, Biondi, Ricardo M., Proschak, Ewgenij, and Zörnig, Martin

Published
2017
Full Text
View/download PDF

104. Prognostic value of paraaortic lymph node metastases in patients with ductal adenocarcinoma of the pancreatic head.

Author

Petrova, Ekaterina, Mazzella, Elena, Trojan, Jörg, Koch, Christine, Schulze, Falko, Bechstein, Wolf O., and Schnitzbauer, Andreas A.

Subjects
LYMPHATIC metastasis, PROGNOSIS, PANCREATIC duct, PROGRESSION-free survival, PANCREATIC cancer
Abstract

The role of paraaortic lymphadenectomy for cancer of the pancreatic head is controversial. The aim of this study is to analyze the prognostic role of paraaortic lymph node (PALN) metastases after resection for ductal adenocarcinoma of the pancreatic head. A retrospective analysis of all patients, who underwent upfront resection for ductal adenocarcinoma of the pancreatic head at the Frankfurt University Hospital from 2011 to 2020 was performed. The primary endpoint was survival, according to the presence of PALN metastases. Out of 468 patients with pancreatic resection, 148 had an upfront resection for ductal adenocarcinoma. Of those, in 125 (85%) a paraaortic lymphadenectomy was performed. In 19 (15.2%) PALN metastases were detected. The estimated overall median survival after resection was 21.7 months (95% CI 18.8 to 26.4), the disease free survival 16 months (95% CI 12 to 18). Among the patients with lymph node metastases, PALN metastases had no significant influence on overall (18.9 versus 19 months, HR = 1.3, 95% CI 0.7 to 2.6, p = 0.392) or disease free survival (14 versus 10.7 months, HR = 1.7, 95% CI 0.9 to 3.2, p = 0.076). After adjusting for T-stage, N-stage, grade, resection margin, PALN metastases, and adjuvant therapy, only adjuvant therapy had a prognostic significance for overall survival (HR = 0.47, 95% CI 0.26 to 0.85, p = 0.013). Patients with ductal adenocarcinoma of the pancreatic head and PALN metastases do not have inferior outcomes than those with regional lymph node metastases. Thus, positive PALN should not be considered a contraindication for resection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

109. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Author

Chan, Henry L Y, primary, Vogel, Arndt, additional, Berg, Thomas, additional, De Toni, Enrico N, additional, Kudo, Masatoshi, additional, Trojan, Jörg, additional, Eiblmaier, Anja, additional, Klein, Hanns‐Georg, additional, Hegel, Johannes Kolja, additional, Sharma, Ashish, additional, Madin, Kairat, additional, Rolny, Vinzent, additional, Lisy, Marcus‐Rene, additional, and Piratvisuth, Teerha, additional

Published
2022
Full Text
View/download PDF

111. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL

Author

Voesch Sabrina, Bitzer Michael, Albert Jörg, Bartenstein Peter, Bechstein Wolf, Blödt Susanne, Brunner Thomas, Dombrowski Frank, Evert Matthias, Follmann Markus, La Fougère Christian, Freudenberger Paul, Geier Andreas, Gkika Eleni, Götz Martin, Hammes Elke, Helmberger Thomas, Hoffmann Ralf-Thorsten, Hofmann Wolf-Peter, Huppert Peter, Kautz Achim, Knötgen Gabi, Körber Jürgen, Krug David, Lammert Frank, Lang Hauke, Langer Thomas, Lenz Philipp, Mahnken Andreas, Meining Alexander, Micke Oliver, Nadalin Silvio, Nguyen Huu Phuc, Ockenga Johann, Oldhafer Karl-Jürgen, Paprottka Philipp, Paradies Kerstin, Pereira Philippe, Persigehl Thorsten, Plauth Mathias, Plentz Ruben, Pohl Jürgen, Riemer Jutta, Reimer Peter, Ringwald Johanna, Ritterbusch Ulrike, Roeb Elke, Schellhaas Barbara, Schirmacher Peter, Schmid Irene, Schuler Andreas, von Schweinitz Dietrich, Seehofer Daniel, Sinn Marianne, Stein Alexander, Stengel Andreas, Steubesand Nadine, Stoll Christian, Tannapfel Andrea, Taubert Anne, Trojan Jörg, van Thiel Ingo, Tholen Reina, Vogel Arndt, Vogl Thomas, Vorwerk Hilke, Wacker Frank, Waidmann Oliver, Wedemeyer Heiner, Wege Henning, Wildner Dane, Wittekind Christian, Wörns Marcus-Alexander, Galle Peter, and Malek Nisar

Subjects
Gastroenterology, Medizin
Abstract

Weitere Nicht-UDE Autoren sind nicht genannt.

Published
2022

113. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

Author

Himmelsbach, Vera, primary, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Venerito, Marino, additional, Sinner, Friedrich, additional, Zimpel, Carolin, additional, Marquardt, Jens U., additional, Trojan, Jörg, additional, Waidmann, Oliver, additional, and Finkelmeier, Fabian, additional

Published
2022
Full Text
View/download PDF

115. Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma

Author

Trojan, Jörg, primary, Hoffmeister, Albrecht, additional, Neu, Bruno, additional, Kasper, Stefan, additional, Dechêne, Alexander, additional, Jürgensen, Christian, additional, Schirra, Jörg, additional, Jakobs, Ralf, additional, Palmer, Dan, additional, Selbo, Pål k., additional, Olivecrona, Hans, additional, Finnesand, Lena, additional, Høgset, Anders, additional, Walday, Per, additional, and Sturgess, Richard, additional

Published
2022
Full Text
View/download PDF

119. Colonization with multidrug‐resistant organisms is associated with impaired survival of patients with surgically resected cholangiocarcinoma.

Author

Kinzler, Maximilian N., Stehle, Angelika, Schulze, Falko, Hogardt, Michael, Wichelhaus, Thomas A., Kempf, Volkhard A. J., Finkelmeier, Fabian, Trojan, Jörg, Zeuzem, Stefan, Schnitzbauer, Andreas A., Bechstein, Wolf O., Wild, Peter J., and Walter, Dirk

Subjects
MULTIDRUG resistance, OVERALL survival, CHOLANGIOCARCINOMA, MULTIDRUG-resistant tuberculosis, MEDICAL screening, MULTIVARIATE analysis
Abstract

Background & Aims: Colonization with multidrug‐resistant organisms (MDRO) has been shown to impair survival in patients with various malignancies. Despite the increasing spread of MDRO, its impact on patients with cholangiocarcinoma (CCA) is unclear. Aim of this study was to analyse the impact of MDRO‐colonization on overall prognosis in CCA patients. Methods: All patients with surgically resected CCA diagnosed between August 2005 and November 2021 at the University Hospital Frankfurt were screened for MDRO. CCA patients with a positive MDRO screening before or within the first 90 days after diagnosis of CCA were defined as colonized. Patients with a negative MDRO screening were defined as non‐colonized. Results: Hundred and sixty nine patients were included. 32% (n = 54) were screened MDRO positive, while 68% (115) were non‐colonized. Median overall survival (OS) for colonized patients was 17.1 months (95% CI = 9–25.2 months) compared to 50 months (95% CI = 37.1–62.8) for MDRO‐negative patients (p ≤.001). Non‐cancer‐related mortality (p ≤.001) and infectious‐related death (p ≤.001) was significantly higher in the MDRO‐colonized group. In multivariate analysis, MDRO colonization (HR = 2.1, 95% CI = 1.4–3.3, p =.001), ECOG 1 (HR = 2.5, 95% CI = 1.6–4, p ≤.001) and N1 status (HR = 1.7, 95% CI = 1.1–2.6, p =.017) were independent risk factors for OS. Conclusion: MDRO‐colonization contributes to poor survival in patients with surgically resected CCA. MDRO surveillance is necessary to optimize clinical management of infections and to potentially reduce mortality in this critical population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

120. Complete pathological response after neoadjuvant short-course immunotherapy with Ipilimumab and Nivolumab in locally advanced MSI-H/dMMR rectal cancer

Author

Trojan, Jörg, Stintzing, Sebastian Jörg, Haase, Oliver, Koch, Christine, Ziegler, Paul, Demes, Melanie Christin, and Jelas, Ivan

Subjects
ddc:610
Abstract

Background: Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. Material and Methods: A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. Results: After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. Conclusion: In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.

Published
2021

127. Influencing the body schema through the feeling of satiety

Author

Baumann, Patricia, Beckmann, Nina, Herpertz, Stephan, Trojan, Jörg, and Diers, Martin

Subjects
Multidisciplinary, Science, Medicine
Abstract

The body schema is a much discussed aspect of body awareness. Although there is still no single definition, there is widespread consensus that the body schema is responsible for movement and interaction with the environment. It usually remains outside of active consciousness. There are only few investigations on influences on the body schema and none of them investigated feeling of satiety or hunger. Thirty-two healthy women were investigated twice, one time sat and the other time hungry. To measure the body schema, we used a door-like-aperture and compared the critical aperture-to-shoulder-ratio (cA/S). A cover story was used to ensure that the unconscious body schema has been measured. We found a significantly higher cA/S for satiety compared to hungry, which indicates that during satiety participants rotate their shoulders for relatively larger door compared to hunger, unconsciously estimating their body size to be larger. We showed that even a moderate rated feeling of hunger or satiety leads to an adjustment in body-scaled action and consequently also an adaptation of body schema. It suggests that, in addition to the visual-spatial and the proprioceptive representation, somatic information can also be relevant for the body schema.

Published
2021

131. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

Author

Al‐Batran, Salah‐Eddin, Hofheinz, Ralf‐Dieter, Reichart, Alexander, Pauligk, Claudia, Schönherr, Caroline, Schlag, Rudolf, Siegler, Gabriele, Dörfel, Steffen, Koenigsmann, Michael, Zahn, Mark‐Oliver, Schubert, Jörg, Aldaoud, Ali, Höffkes, Heinz‐Gert, Schulz, Holger, Hahn, Lars, Uhlig, Jens, Blau, Wolfgang, Stauch, Martina, Weniger, Jörg, Wolf, Martin, Jacobasch, Lutz, Bildat, Stephan, Wehmeyer, Jürgen, Homann, Nils, Trojan, Jörg, Waidmann, Oliver, Fietz, Thomas, Feustel, Hans‐Peter, Groschek, Matthias, Wierecky, Jan, Waibel, Karin, Mahlmann, Stefan, Schwindel, Uwe, Peters, Uwe, Schuch, Gunter, Pink, Daniel, Eschenburg, Henning, Wörns, Marcus‐A., Harich, Hans‐Detlev, Weikersthal, Ludwig Fischer, Däßler, Klaus‐Ulrich, Behringer, Dirk M., Messmann, Helmut, Kretzschmar, Albrecht, Gallmeier, Eike, Forstbauer, Helmut, Kunzmann, Volker, Papke, Jens, Büchner‐Steudel, Petra, Vehling‐Kaiser, Ursula, Springfeld, Christoph, Vogel, Arndt, Ettrich, Thomas J., Schaaf, Marina, Hausen, Gerrit zur, and Götze, Thorsten Oliver

Published
2021

132. Combination of sorafenib and transarterial chemoembolization in selected patients with advanced-stage hepatocellular carcinoma: a retrospective cohort study at three german liver centers

Author

Koch, Christine, Göller, Markus, Schott, Eckart, Waidmann, Oliver, Winkel, Mark op den, Paprottka, Philipp Marius, Zangos, Stephan, Vogel, Thomas, Bechstein, Wolf Otto, Zeuzem, Stefan, Kolligs, Frank Thomas, Trojan, Jörg, Koch, Christine, Göller, Markus, Schott, Eckart, Waidmann, Oliver, Winkel, Mark op den, Paprottka, Philipp Marius, Zangos, Stephan, Vogel, Thomas, Bechstein, Wolf Otto, Zeuzem, Stefan, Kolligs, Frank Thomas, and Trojan, Jörg

Abstract

Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.

Published
2021

137. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study

Author

Patel, Nikunj, primary, Maher, Joshua, additional, Lie, Xandra, additional, Gwaltney, Chad, additional, Barzi, Afsaneh, additional, Karwal, Mark, additional, Macarulla, Teresa, additional, Sun, Hui-Chuan, additional, Trojan, Jörg, additional, Meyers, Oren, additional, Workman, Christina, additional, Morgan, Shethah, additional, Negro, Alejandra, additional, and Cohen, Gordon, additional

Published
2021
Full Text
View/download PDF

139. Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers

Author

Koch, Christine, primary, Göller, Markus, additional, Schott, Eckart, additional, Waidmann, Oliver, additional, op den Winkel, Mark, additional, Paprottka, Philipp, additional, Zangos, Stephan, additional, Vogl, Thomas, additional, Bechstein, Wolf Otto, additional, Zeuzem, Stefan, additional, Kolligs, Frank T., additional, and Trojan, Jörg, additional

Published
2021
Full Text
View/download PDF

142. Cetuximab-mediated protection from hypoxia-induced cell death: implications for therapy sequence in colorectal cancer

Author

Urban, Hans, Maurer, Gabriele Dorothea, Luger, Anna-Luisa, Lorenz, Nadja I., Sauer, Benedikt, Stroh, Christopher, Trojan, Jörg, Mittelbronn, Michel, Steinbach, Joachim Peter, Harter, Patrick Nikolaus, and Ronellenfitsch, Michael Wilfried

Subjects
ddc:610, neoplasms, digestive system diseases
Abstract

Simple Summary: Therapeutic antibodies are an integral part of treatment regimens for metastasized colorectal cancer. In KRAS wildtype tumors both bevacizumab and cetuximab are active. While bevacizumab has previously been shown to induce tumor hypoxia, we here report that EGFR inhibition by cetuximab protects colon cancer cells from hypoxia-induced cell death. This effect appears to be responsible for the inferior efficacy of a treatment sequence of bevacizumab followed by cetuximab versus an inverse sequence that we observed in a colorectal cancer mouse model. It also offers a mechanistic explanation for effects observed in clinical trials such as underadditive or even detrimental effects when combining bevacizumab and cetuximab (CAIRO2 trial) and the superior efficacy of first line cetuximab (FIRE-3 trial) under chemotherapy backbones in colorectal cancer. Abstract: Monoclonal antibodies like cetuximab, targeting the epidermal growth factor receptor (EGFR), and bevacizumab, targeting the vascular endothelial growth factor (VEGF), are an integral part of treatment regimens for metastasized colorectal cancer. However, inhibition of the EGFR has been shown to protect human glioma cells from cell death under hypoxic conditions. In colon carcinoma cells, the consequences of EGFR blockade in hypoxia (e.g., induced by bevacizumab) have not been evaluated yet. LIM1215 and SW948 colon carcinoma and LNT-229 glioblastoma cells were treated with cetuximab, PD153035, and erlotinib and analyzed for cell density and viability. The sequential administration of either cetuximab followed by bevacizumab (CET->BEV) or bevacizumab followed by cetuximab (BEV->CET) was investigated in a LIM1215 (KRAS wildtype) and SW948 (KRAS mutant) xenograft mouse model. In vitro, cetuximab protected from hypoxia. In the LIM1215 model, a survival benefit with cetuximab and bevacizumab monotherapy was observed, but only the sequence CET->BEV showed an additional benefit. This effect was confirmed in the SW948 model. Our observations support the hypothesis that bevacizumab modulates the tumor microenvironment (e.g., by inducing hypoxia) where cetuximab could trigger protective effects when administered later on. The sequence CET->BEV therefore seems to be superior as possible mutual adverse effects are bypassed.

Published
2020

143. Publisher Correction:The Scales Project, a cross-national dataset on the interpretation of thermal perception scales

Author

Schweiker, Marcel, Abdul-Zahra, Amar, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azadeh, Montazami, Azar, Elie, Bahareh, Bannazadeh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera Escudero, Jessica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kania, Renate, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C.Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, McGill, Gráinne, Mino Rodríguez, Isabel, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, María Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, Zomorodian, Zahra Sadat, Universidad de Sevilla. Departamento de Construcciones Arquitectónicas I (ETSA), and Universidad de Sevilla. TEP130: Arquitectura, Patrimonio y Sostenibilidad: Acústica, Iluminación, Óptica y Energía

Published
2020

144. Erratum: Publisher Correction: The Scales Project, a cross-national dataset on the interpretation of thermal perception scales (Scientific data (2019) 6 1 (289))

Author

Schweiker, Marcel, Abdul-Zahra, Amar, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azadeh, Montazami, Azar, Elie, Bahareh, Bannazadeh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, Vecchi, Renata De, Dhaka, Shivraj, Domínguez-Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera, Jesica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kania, Renate, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C.Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín-Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, McGill, Gráinne, Mino-Rodriguez, Isabel, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Ligia, Pérez-Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, Ma Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata-Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, Zomorodian, Zahra Sadat, Physiology, and Amsterdam Movement Sciences

Subjects
SDG 16 - Peace, SDG 16 - Peace, Justice and Strong Institutions, Justice and Strong Institutions
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

146. Evaluating assumptions of scales for subjective assessment of thermal environments – Do laypersons perceive them the way, we researchers believe?

Author

Universidad de Sevilla. Departamento de Construcciones Arquitectónicas I (ETSA), Universidad de Sevilla. TEP130: Arquitectura, Patrimonio y Sostenibilidad: Acústica, Iluminación, Óptica y Energía, Schweiker, Marcel, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azar, Elie, Bannazadeh, Bahareh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera Escudero, Jessica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C. Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, Mino Rodríguez, Isabel, Montazami, Azadeh, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, María Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, Zomorodian, Zahra Sadat, Universidad de Sevilla. Departamento de Construcciones Arquitectónicas I (ETSA), Universidad de Sevilla. TEP130: Arquitectura, Patrimonio y Sostenibilidad: Acústica, Iluminación, Óptica y Energía, Schweiker, Marcel, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azar, Elie, Bannazadeh, Bahareh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera Escudero, Jessica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C. Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, Mino Rodríguez, Isabel, Montazami, Azadeh, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, María Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, and Zomorodian, Zahra Sadat

Abstract

People's subjective response to any thermal environment is commonly investigated by using rating scales describing the degree of thermal sensation, comfort, and acceptability. Subsequent analyses of results collected in this way rely on the assumption that specific distances between verbal anchors placed on the scale exist and that relationships between verbal anchors from different dimensions that are assessed (e.g. thermal sensation and comfort) do not change. Another inherent assumption is that such scales are independent of the context in which they are used (climate zone, season, etc.). Despite their use worldwide, there is indication that contextual differences influence the way the scales are perceived and therefore question the reliability of the scales’ interpretation. To address this issue, a large international collaborative questionnaire study was conducted in 26 countries, using 21 different languages, which led to a dataset of 8225 questionnaires. Results, analysed by means of robust statistical techniques, revealed that only a subset of the responses are in accordance with the mentioned assumptions. Significant differences appeared between groups of participants in their perception of the scales, both in relation to distances of the anchors and relationships between scales. It was also found that respondents’ interpretations of scales changed with contextual factors, such as climate, season, and language. These findings highlight the need to carefully consider context-dependent factors in interpreting and reporting results from thermal comfort studies or post-occupancy evaluations, as well as to revisit the use of rating scales and the analysis methods used in thermal comfort studies to improve their reliability.

Published
2020

147. Publisher Correction:The Scales Project, a cross-national dataset on the interpretation of thermal perception scales

Author

Universidad de Sevilla. Departamento de Construcciones Arquitectónicas I (ETSA), Universidad de Sevilla. TEP130: Arquitectura, Patrimonio y Sostenibilidad: Acústica, Iluminación, Óptica y Energía, Schweiker, Marcel, Abdul-Zahra, Amar, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azadeh, Montazami, Azar, Elie, Bahareh, Bannazadeh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera Escudero, Jessica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kania, Renate, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C.Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, McGill, Gráinne, Mino Rodríguez, Isabel, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, María Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, Zomorodian, Zahra Sadat, Universidad de Sevilla. Departamento de Construcciones Arquitectónicas I (ETSA), Universidad de Sevilla. TEP130: Arquitectura, Patrimonio y Sostenibilidad: Acústica, Iluminación, Óptica y Energía, Schweiker, Marcel, Abdul-Zahra, Amar, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azadeh, Montazami, Azar, Elie, Bahareh, Bannazadeh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera Escudero, Jessica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M., Jin, Quan, Jowkar, Mina, Kania, Renate, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M. C.Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, McGill, Gráinne, Mino Rodríguez, Isabel, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, María Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, and Zomorodian, Zahra Sadat

Published
2020

148. Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patients

Author

Dechêne, Alexander, Kasper, Stefan, Olivecrona, Hans, Schirra, Jörg, Trojan, Jörg, Dechêne, Alexander, Kasper, Stefan, Olivecrona, Hans, Schirra, Jörg, and Trojan, Jörg

Abstract

Photochemical internalization (PCI) is a technology to induce a localized, intracellular enhancement of therapeutics that are processed through endosomal pathways, including gemcitabine in malignant cells. In addition to a direct phototoxic and tumoricidal effect, PCI specifically disrupts endosomal membranes and, thereby, the compartmentalization of certain cytotoxic compounds to enhance a drug’s intended intracellular target reach within the tissue treated. Non-resectable extrahepatic cholangiocarcinoma (eCCA) is a common primary tumor and gemcitabine/cisplatin chemotherapy is widely considered standard of care for it. PCI is well suited as an endoscopic intervention, and clinical observations in three subjects participating in a phase I/IIa dose escalation safety trial are described. The trial included patients with perihilar, non-resectable CCA suitable for standard-of-care chemotherapy. Per protocol, a single endoscopic PCI procedure with gemcitabine was conducted at the initiation of standard gemcitabine/cisplatin therapy. Sixteen patients enrolled in the initial dose escalation phase of the trial, which later was extended to explore the safety of a second PCI procedure during chemotherapy. While limited to a case series, the various clinical observations described here serve to illustrate the effects of localized, perihilar tumor targeting in appropriate patients by any safe methodology, including PCI. As previously indicated by clinical data using other localized treatment modalities, adding a directed, tumor-targeting treatment to systemic therapy to ameliorate the progressively expanding extrahepatic tumor burden can have important effects on the overall outcome of systemic treatment in many patients who have incurable eCCA.

Published
2020

149. AFP ratio predicts HCC recurrence after liver transplantation

Author

Alpini, Gianfranco, Koch, Christine, Bette, Theresa, Waidmann, Oliver, Filmann, Natalie, Schrecker, Christopher, Trojan, Jörg, Weiler, Nina, Vermehren, Johannes, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, Herrmann, Eva, Welker, Martin-Walter, Alpini, Gianfranco, Koch, Christine, Bette, Theresa, Waidmann, Oliver, Filmann, Natalie, Schrecker, Christopher, Trojan, Jörg, Weiler, Nina, Vermehren, Johannes, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, Herrmann, Eva, and Welker, Martin-Walter

Abstract

Background/aims: Hepatocellular carcinoma (HCC) is a leading indication for liver transplantation (LT) worldwide. Early identification of patients at risk for HCC recurrence is of paramount importance since early treatment of recurrent HCC after LT may be associated with increased survival. We evaluated incidence of and predictors for HCC recurrence, with a focus on the course of AFP levels. Methods: We performed a retrospective, single-center study of 99 HCC patients who underwent LT between January 28th, 1997 and May 11th, 2016. A multi-stage proportional hazards model with three stages was used to evaluate potential predictive markers, both by univariate and multivariable analysis, for influences on 1) recurrence after transplantation, 2) mortality without HCC recurrence, and 3) mortality after recurrence. Results: 19/99 HCC patients showed recurrence after LT. Waiting time was not associated with overall HCC recurrence (HR = 1, p = 0.979). Similarly, waiting time did not affect mortality in LT recipients both with (HR = 0.97, p = 0.282) or without (HR = 0.99, p = 0.685) HCC recurrence. Log10-transformed AFP values at the time of LT (HR 1.75, p = 0.023) as well as after LT (HR 2.07, p = 0.037) were significantly associated with recurrence. Median survival in patients with a ratio (AFP at recurrence divided by AFP 3 months before recurrence) of 0.5 was greater than 70 months, as compared to a median of only 8 months in patients with a ratio of 5. Conclusion: A rise in AFP levels rather than an absolute threshold could help to identify patients at short-term risk for HCC recurrence post LT, which may allow intensification of the surveillance strategy on an individualized basis.

Published
2020

150. Evaluating assumptions of scales for subjective assessment of thermal environments – Do laypersons perceive them the way, we researchers believe?

Author

Schweiker, Marcel, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azar, Elie, Bannazadeh, Bahareh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon-Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez-Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera, Jesica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M, Jin, Quan, Jowkar, Mina, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M.C. Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín-Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, Mino-Rodriguez, Isabel, Montazami, Azadeh, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez-Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, Ma Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata-Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, Zomorodian, ZahraSadat, Schweiker, Marcel, André, Maíra, Al-Atrash, Farah, Al-Khatri, Hanan, Alprianti, Rea Risky, Alsaad, Hayder, Amin, Rucha, Ampatzi, Eleni, Arsano, Alpha Yacob, Azar, Elie, Bannazadeh, Bahareh, Batagarawa, Amina, Becker, Susanne, Buonocore, Carolina, Cao, Bin, Choi, Joon-Ho, Chun, Chungyoon, Daanen, Hein, Damiati, Siti Aisyah, Daniel, Lyrian, De Vecchi, Renata, Dhaka, Shivraj, Domínguez-Amarillo, Samuel, Dudkiewicz, Edyta, Edappilly, Lakshmi Prabha, Fernández-Agüera, Jesica, Folkerts, Mireille, Frijns, Arjan, Gaona, Gabriel, Garg, Vishal, Gauthier, Stephanie, Jabbari, Shahla Ghaffari, Harimi, Djamila, Hellwig, Runa T., Huebner, Gesche M, Jin, Quan, Jowkar, Mina, Kim, Jungsoo, King, Nelson, Kingma, Boris, Koerniawan, M. Donny, Kolarik, Jakub, Kumar, Shailendra, Kwok, Alison, Lamberts, Roberto, Laska, Marta, Lee, M.C. Jeffrey, Lee, Yoonhee, Lindermayr, Vanessa, Mahaki, Mohammadbagher, Marcel-Okafor, Udochukwu, Marín-Restrepo, Laura, Marquardsen, Anna, Martellotta, Francesco, Mathur, Jyotirmay, Mino-Rodriguez, Isabel, Montazami, Azadeh, Mou, Di, Moujalled, Bassam, Nakajima, Mia, Ng, Edward, Okafor, Marcellinus, Olweny, Mark, Ouyang, Wanlu, Papst de Abreu, Ana Lígia, Pérez-Fargallo, Alexis, Rajapaksha, Indrika, Ramos, Greici, Rashid, Saif, Reinhart, Christoph F., Rivera, Ma Isabel, Salmanzadeh, Mazyar, Schakib-Ekbatan, Karin, Schiavon, Stefano, Shooshtarian, Salman, Shukuya, Masanori, Soebarto, Veronica, Suhendri, Suhendri, Tahsildoost, Mohammad, Tartarini, Federico, Teli, Despoina, Tewari, Priyam, Thapa, Samar, Trebilcock, Maureen, Trojan, Jörg, Tukur, Ruqayyatu B., Voelker, Conrad, Yam, Yeung, Yang, Liu, Zapata-Lancaster, Gabriela, Zhai, Yongchao, Zhu, Yingxin, and Zomorodian, ZahraSadat

Abstract

People's subjective response to any thermal environment is commonly investigated by using rating scales describing the degree of thermal sensation, comfort, and acceptability. Subsequent analyses of results collected in this way rely on the assumption that specific distances between verbal anchors placed on the scale exist and that relationships between verbal anchors from different dimensions that are assessed (e.g. thermal sensation and comfort) do not change. Another inherent assumption is that such scales are independent of the context in which they are used (climate zone, season, etc.). Despite their use worldwide, there is indication that contextual differences influence the way the scales are perceived and therefore question the reliability of the scales’ interpretation. To address this issue, a large international collaborative questionnaire study was conducted in 26 countries, using 21 different languages, which led to a dataset of 8225 questionnaires. Results, analysed by means of robust statistical techniques, revealed that only a subset of the responses are in accordance with the mentioned assumptions. Significant differences appeared between groups of participants in their perception of the scales, both in relation to distances of the anchors and relationships between scales. It was also found that respondents’ interpretations of scales changed with contextual factors, such as climate, season, and language. These findings highlight the need to carefully consider context-dependent factors in interpreting and reporting results from thermal comfort studies or post-occupancy evaluations, as well as to revisit the use of rating scales and the analysis methods used in thermal comfort studies to improve their reliability.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results